The study sponsored by Istituto Clinico Humanitas aims to develop a diagnostic assay based on the detection of EMT-TFs mRNA levels in blood samples from colorectal cancer (CRC) patients. This approach could enhance early diagnosis, disease progression monitoring, and recurrence risk assessment, potentially positioning the assay as a valuable tool in the liquid biopsy market. Given the increasing focus on non-invasive diagnostic methods, this study may attract interest from pharmaceutical companies and diagnostic firms looking to expand their oncology portfolios. Competitive implications include the need to assess existing liquid biopsy technologies and their efficacy in CRC diagnosis, as well as the potential for partnerships or acquisitions in the biomarker space.